All Medicines
Dr. Aditya Singh

Medically Reviewed By

Dr. Aditya Singh, MBBS, MD (Pharmacology)

Reg No: MCI-654321 • Verified Medical Reviewer

Antineoplastic agents

Lumoxiti

(moxetumomab pasudotox)

Uses, side effects, dosage information & price range

AstraZeneca AB

About this medicine

Lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (HCL) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (PNA).

Common Substitutes & Alternatives

These medicines share the same salt composition or therapeutic category and can be used as substitutes under professional medical supervision.

PoherdyComposition: pertuzumabOrganon N.V.
Price on RequestView Details →
MekinistComposition: trametinibNovartis Europharm Limited
Price on RequestView Details →
VijoiceComposition: alpelisibNovartis Europharm Limited
Price on RequestView Details →
KisqaliComposition: ribociclibNovartis Europharm Limited
Price on RequestView Details →
TecartusComposition: brexucabtagene autoleucelKite Pharma EU B.V.
Price on RequestView Details →

Key Information

Salt / Composition

moxetumomab pasudotox

Category

Antineoplastic agents

Manufacturer

AstraZeneca AB

Need a doctor's consultation?

Don't self-medicate. Consult a doctor before taking any medicine.

Medical Disclaimer

This information is for educational purposes only and is not a substitute for professional medical advice. Always consult your doctor or pharmacist before taking any medication. Prices are indicative and may vary. Do not start, stop, or change the dosage of any medicine without your doctor's approval.

Disclaimer:Content on this page is for informational purposes only. Do not consume prescription medication without a registered practitioner's direct oversight.